Eptifibatide Acetate (19-88627-80-7)

  • For any enquiries about this API or any of Tofigh Daru’s other products, please contact:
  • Contact Us >>

Product Detail

Mechanism:

Eptifibatide is of the glycoprotein IIb/IIIa inhibitor class and is derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycine-aspartat-mimetics and reversibly binds to platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.

Packaging: Glass bottle

Storage conditions: Preserve in tight, light-resistant containers in cool palace

CAS Number:  19-88627-80-7

Formula:  C35H49N11O9S2.xC2H4O2

Molecular Weight: 831.96 (free base basis)

Method of Analysis:  In house monograph

Application:

Eptifibatide is a synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation.
Eptifibatide has a short half-life and is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
Therefore, Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention.